STOCKNO.DE
Institutional ownership intelligence
Research
Schedule 13G/A

RDPTF Schedule 13G/A filing by JPMorgan Chase / Asset Management

JPMorgan Chase / Asset Management reported beneficial ownership of 145.7M shares, representing 12% of Radiopharm Theranostics Ltd in this filing.

FiledJan 16, 2026
Ownership dateDec 31, 2025
Reported shares145.7M
Reported ownership12%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 145.7M
Shared voting power 145.7M
Sole dispositive power 145.7M
Shared dispositive power 145.7M
Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$0.02as of Jan 16, 2026
Latest tracked price$0.01as of Aug 4, 2026
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
JPMorgan Chase / Asset Management
CIK
CIK0000019617
Accession
0000019617-26-000027
Form
Schedule 13G/A
Open SEC filing View RDPTF ownership history
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →